Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. reports recurring updates about its pharmaceutical royalty business, which owns rights to royalties from licensed pharmaceutical products and no longer conducts research and development or commercial operations. The company’s news is centered on license revenue, primarily under the Mayne License Agreement, changes in sales of licensed products, operating expense levels after its transition to a royalty-based model, and results from continuing operations.
TherapeuticsMD also provides corporate strategy updates, including disclosures about its ongoing evaluation of strategic alternatives. Its historical context includes a December 2022 shift from a women’s healthcare commercialization business to a company focused on collecting royalties from licensees.
TherapeuticsMD (NASDAQ: TXMD) reported first quarter 2026 results for the period ended March 31, 2026.
Net income from continuing operations was $103 thousand, compared to a net loss of $636 thousand a year earlier. License revenue from continuing operations was $724 thousand, up $331 thousand from $393 thousand, mainly from the Mayne License Agreement. Total operating expenses fell 13.6% to $1,447 thousand from $1,674 thousand, driven by the absence of prior write-off expense and lower professional fees and share-based compensation. The company continues to evaluate potential strategic alternatives, including possible acquisitions, mergers, asset sales, or other transactions, without a set timetable or assurance of completion. Cash and cash equivalents totaled $8.4 million at March 31, 2026.
TherapeuticsMD (NASDAQ: TXMD) reported full year 2025 results with improved profitability and higher license revenue. Net loss from continuing operations narrowed to $0.7 million (loss per share $0.06), versus a $2.3 million loss in 2024.
License revenue rose to $3.0 million (a 71.6% increase). Total operating expenses declined to $7.4 million. The company held $7.5 million in cash and is actively evaluating strategic alternatives, with no timetable or assurance of a transaction.
TherapeuticsMD (NASDAQ: TXMD) reported third quarter 2025 results for the three months ended September 30, 2025. The company posted net income from continuing operations of $50,000 (approximately $0.00 per share) versus a net loss of $567,000 (about $0.05 per share) in Q3 2024. License revenue, primarily from the Mayne license agreement, was $784,000, up $237,000 year-over-year. Total operating expenses were $1.646 million, relatively flat versus prior year. The company reported $7.1 million in cash and cash equivalents as of September 30, 2025. Management said it is continuing to evaluate strategic alternatives with no timetable or assurance of a transaction.
TherapeuticsMD (NASDAQ: TXMD) reported positive Q2 2025 financial results, marking a significant turnaround with net income of $545,000 ($0.05 per share) compared to a net loss of $(1.05) million in Q2 2024. License revenues, primarily from the Mayne License Agreement, increased to $1.0 million, up from $234,000 year-over-year.
Operating expenses decreased by 45.5% to $1.647 million, mainly due to an impairment charge recorded in Q2 2024. The company ended the quarter with $6.1 million in cash and is actively evaluating strategic alternatives, including potential mergers, acquisitions, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q1 2025 financial results, showing a reduced net loss from continuing operations of $(636) thousand ($(0.06) per share), compared to $(809) thousand ($(0.07) per share) in Q1 2024. License revenues increased 25.8% to $393 thousand, primarily from the Mayne License Agreement, up from $313 thousand in Q1 2024. Operating expenses decreased 13.1% to $1,264 thousand due to improved efficiencies as a royalty-based business.
The company maintains $5.7 million in cash and cash equivalents as of March 31, 2025. TherapeuticsMD is actively evaluating strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales, though no specific timeline or guaranteed outcome has been established.
TherapeuticsMD (NASDAQ: TXMD) has reported its full year 2024 financial results, showing improved performance with a reduced net loss from continuing operations of $(2.3) million, or $(0.20) per share, compared to $(7.7) million, or $(0.74) per share in 2023.
The company's license revenue, primarily from the Mayne License Agreement, increased by 35.3% to $1.8 million in 2024, up from $1.3 million in 2023. Operating expenses decreased by 33.6% to $6.5 million from $9.8 million in 2023, reflecting the company's transition from a commercial to a royalty-based business model.
As of December 31, 2024, TXMD maintained $5.1 million in cash and cash equivalents. The company is currently evaluating strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q3 2024 financial results, showing a reduced net loss of $(567) thousand ($(0.05) per share) compared to $(1.4) million ($(0.13) per share) in Q3 2023. License revenue, mainly from the Mayne License Agreement, increased to $547 thousand from $(53) thousand in Q3 2023. Operating expenses decreased by 18.3% to $1.4 million. The company ended the quarter with $5.0 million in cash and cash equivalents. TherapeuticsMD is currently evaluating strategic alternatives, including potential mergers, acquisitions, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q2 2024 financial results. The company, which owns pharmaceutical royalty rights, saw a net loss from continuing operations of $1.05 million ($0.09 per share), an improvement from the $2.4 million loss in Q2 2023. License revenue decreased by 46.5% to $234,000, primarily due to changes in sales of licensed products. Total operating expenses decreased by 8.1% to $2.7 million, reflecting cost optimization efforts. The company's cash and cash equivalents stood at $5.2 million as of June 30, 2024. TherapeuticsMD is currently evaluating strategic alternatives, including potential acquisitions, mergers, or asset sales.
TherapeuticsMD, Inc. reported its First Quarter 2024 Financial Results, showing a net loss from continuing operations of $(0.8) million, or $(0.07) per share, compared to $(2.3) million in 2023. The company generated approximately $1.2 million in gross license royalties under the Mayne License Agreement, with total operating expenses decreasing by 52.8% to $1.5 million. Additionally, the company is exploring various strategic alternatives without a set timetable for completion.
Summary not available.